
Sign up to save your podcasts
Or
Do psychedelics treat mental illness? In this GameChanger episode host, Geoff Wall and guest, Sarah Grady, a psychiatric pharmacist, discuss a recent NEJM article comparing psilocybin (magic mushrooms) to escitalopram.
Guest:
Sarah Grady, PharmD
Drake University
Redeem your CPE or CME credit here with your GameChangers Subscription!
We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964
References and resources:
Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021 Apr 15;384(15):1402-1411. doi: 10.1056/NEJMoa2032994. PMID: 33852780.
Continuing Education Information:
Learning Objectives:
1. Discuss a recent study comparing psilocybin to escitalopram in depression
2. Identify potential patients that could benefit from psilocybin based on the study
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-231-H01-P
Initial release date: 8/3/21
Expiration date: 8/3/22
Dr. Sarah Grady reports no actual or potential conflicts of interest associated with this activity.
Complete CPE & CME details can be found here.
Follow CEimpact on Social Media:
LinkedIn
Instagram
4.8
1616 ratings
Do psychedelics treat mental illness? In this GameChanger episode host, Geoff Wall and guest, Sarah Grady, a psychiatric pharmacist, discuss a recent NEJM article comparing psilocybin (magic mushrooms) to escitalopram.
Guest:
Sarah Grady, PharmD
Drake University
Redeem your CPE or CME credit here with your GameChangers Subscription!
We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964
References and resources:
Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021 Apr 15;384(15):1402-1411. doi: 10.1056/NEJMoa2032994. PMID: 33852780.
Continuing Education Information:
Learning Objectives:
1. Discuss a recent study comparing psilocybin to escitalopram in depression
2. Identify potential patients that could benefit from psilocybin based on the study
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-231-H01-P
Initial release date: 8/3/21
Expiration date: 8/3/22
Dr. Sarah Grady reports no actual or potential conflicts of interest associated with this activity.
Complete CPE & CME details can be found here.
Follow CEimpact on Social Media:
LinkedIn
Instagram
107 Listeners
495 Listeners
43,334 Listeners
12,636 Listeners
3,321 Listeners
1,108 Listeners
719 Listeners
3,474 Listeners
9,269 Listeners
1,202 Listeners
1,301 Listeners
2,028 Listeners
4,440 Listeners
2,027 Listeners
19,371 Listeners